Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]
Verrica Pharmaceuticals Inc. (VRCA)
Last verrica pharmaceuticals inc. earnings: 3/13 07:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Full-Year Revenue : Full-year revenue for YCANTH totaled $4.7 million. Insurance Coverage : Over 200 million lives now covered on commercial insurance and managed Medicaid plans. Net Loss : Reported a net loss of $24.6 million for the fourth quarter and $67.0 million for the full year. Research and Development : Continued advancement in the pipeline, including a Phase 3 clinical trial for common warts treatment and a Phase 2 study for basal cell carcinoma. Cash Position : Cash and cash equivalents stood at $69.5 million as of December 31, 2023. Non-GAAP Financial Measures : Adjusted net loss per share for the full year 2023 was $1.14, compared to $0.51 for the previous year. Warning! GuruFocus has detected 5 Warning Signs with VRCA. On February 29, 2024, Verrica Pharmaceuticals Inc ( NASDAQ:VRCA ) released its 8-K filing , detailing the financial results for the fourth quarter and full year ended December 31, 2023. Verrica, a dermatology therapeutics company, is known f
Show less
Read more
Impact Snapshot
Event Time:
VRCA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRCA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRCA alerts
High impacting Verrica Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VRCA
News
- Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.MarketBeat
- Strong week for Verrica Pharmaceuticals (NASDAQ:VRCA) shareholders doesn't alleviate pain of three-year loss [Yahoo! Finance]Yahoo! Finance
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA [Yahoo! Finance]Yahoo! Finance
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAGlobeNewswire
VRCA
Earnings
- 2/29/24 - Miss
VRCA
Sec Filings
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- 4/19/24 - Form DEF
- VRCA's page on the SEC website